Computational Study to Determine When to Initiate and Alternate Therapy in HIV Infection

HIV is a widespread viral infection without cure. Drug treatment has transformed HIV disease into a treatable long-term infection. However, the appearance of mutations within the viral genome reduces the susceptibility of HIV to drugs. Therefore, a key goal is to extend the time until patients exhib...

Full description

Bibliographic Details
Main Authors: Matthias Haering, Andreas Hördt, Michael Meyer-Hermann, Esteban A. Hernandez-Vargas
Format: Article
Language:English
Published: Hindawi Limited 2014-01-01
Series:BioMed Research International
Online Access:http://dx.doi.org/10.1155/2014/472869
id doaj-22ab12f3912a4007a16c08e02432c893
record_format Article
spelling doaj-22ab12f3912a4007a16c08e02432c8932020-11-24T22:01:44ZengHindawi LimitedBioMed Research International2314-61332314-61412014-01-01201410.1155/2014/472869472869Computational Study to Determine When to Initiate and Alternate Therapy in HIV InfectionMatthias Haering0Andreas Hördt1Michael Meyer-Hermann2Esteban A. Hernandez-Vargas3Department of Systems Immunology and Braunschweig Integrated Centre of Systems Biology, Helmholtz Centre for Infection Research, Inhoffenstraße 7, 38124 Braunschweig, GermanyInstitut für Geophysik und extraterrestrische Physik, Technische Universität Braunschweig, Mendelssohnstraße 3, 38106 Braunschweig, GermanyDepartment of Systems Immunology and Braunschweig Integrated Centre of Systems Biology, Helmholtz Centre for Infection Research, Inhoffenstraße 7, 38124 Braunschweig, GermanyDepartment of Systems Immunology and Braunschweig Integrated Centre of Systems Biology, Helmholtz Centre for Infection Research, Inhoffenstraße 7, 38124 Braunschweig, GermanyHIV is a widespread viral infection without cure. Drug treatment has transformed HIV disease into a treatable long-term infection. However, the appearance of mutations within the viral genome reduces the susceptibility of HIV to drugs. Therefore, a key goal is to extend the time until patients exhibit resistance to all existing drugs. Current HIV treatment guidelines seem poorly supported as practitioners have not achieved a consensus on the optimal time to initiate and to switch antiretroviral treatments. We contribute to this discussion with predictions derived from a mathematical model of HIV dynamics. Our results indicate that early therapy initiation (within 2 years postinfection) is critical to delay AIDS progression. For patients who have not received any therapy during the first 3 years postinfection, switch in response to virological failure may outperform proactive switching strategies. In case that proactive switching is opted, the switching time between therapies should not be larger than 100 days. Further clinical trials are needed to either confirm or falsify these predictions.http://dx.doi.org/10.1155/2014/472869
collection DOAJ
language English
format Article
sources DOAJ
author Matthias Haering
Andreas Hördt
Michael Meyer-Hermann
Esteban A. Hernandez-Vargas
spellingShingle Matthias Haering
Andreas Hördt
Michael Meyer-Hermann
Esteban A. Hernandez-Vargas
Computational Study to Determine When to Initiate and Alternate Therapy in HIV Infection
BioMed Research International
author_facet Matthias Haering
Andreas Hördt
Michael Meyer-Hermann
Esteban A. Hernandez-Vargas
author_sort Matthias Haering
title Computational Study to Determine When to Initiate and Alternate Therapy in HIV Infection
title_short Computational Study to Determine When to Initiate and Alternate Therapy in HIV Infection
title_full Computational Study to Determine When to Initiate and Alternate Therapy in HIV Infection
title_fullStr Computational Study to Determine When to Initiate and Alternate Therapy in HIV Infection
title_full_unstemmed Computational Study to Determine When to Initiate and Alternate Therapy in HIV Infection
title_sort computational study to determine when to initiate and alternate therapy in hiv infection
publisher Hindawi Limited
series BioMed Research International
issn 2314-6133
2314-6141
publishDate 2014-01-01
description HIV is a widespread viral infection without cure. Drug treatment has transformed HIV disease into a treatable long-term infection. However, the appearance of mutations within the viral genome reduces the susceptibility of HIV to drugs. Therefore, a key goal is to extend the time until patients exhibit resistance to all existing drugs. Current HIV treatment guidelines seem poorly supported as practitioners have not achieved a consensus on the optimal time to initiate and to switch antiretroviral treatments. We contribute to this discussion with predictions derived from a mathematical model of HIV dynamics. Our results indicate that early therapy initiation (within 2 years postinfection) is critical to delay AIDS progression. For patients who have not received any therapy during the first 3 years postinfection, switch in response to virological failure may outperform proactive switching strategies. In case that proactive switching is opted, the switching time between therapies should not be larger than 100 days. Further clinical trials are needed to either confirm or falsify these predictions.
url http://dx.doi.org/10.1155/2014/472869
work_keys_str_mv AT matthiashaering computationalstudytodeterminewhentoinitiateandalternatetherapyinhivinfection
AT andreashordt computationalstudytodeterminewhentoinitiateandalternatetherapyinhivinfection
AT michaelmeyerhermann computationalstudytodeterminewhentoinitiateandalternatetherapyinhivinfection
AT estebanahernandezvargas computationalstudytodeterminewhentoinitiateandalternatetherapyinhivinfection
_version_ 1725838779878473728